Infectious DiseaseMerck
Merck and Gilead Report Phase 3 Results for Once-Weekly Oral HIV Treatment Combination
BMI
Biotechnology Media Insights
Editorial Team · July 8, 2025
Merck and Gilead Sciences announce Phase 3 results for once-weekly oral islatravir plus lenacapavir combination showing non-inferior HIV viral suppression.
Merck and Gilead Sciences today announced Phase 3 results from the ILLUMINATE-B trial evaluating once-weekly oral islatravir plus lenacapavir for HIV treatment. The trial demonstrated non-inferiority to daily oral standard-of-care regimens in maintaining HIV viral suppression at 52 weeks.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.